LABORATORY AND CLINICAL STUDIES ON CEFTAZIDIME

Abstract

Ceftazidime, a new antibacterial agent, was studied in vitro and clinically. The results were as follows
1) Antibacterial activity
Ceftazidime was shown to have excellent antibacterial activity against clinically isolated E. coil, P. mirabilis, Indole (+) Proteus, K. pneumoniae, S. marcescens and P. aeruginosa. It also had relatively high activity against clinically isolated Enterobacter spp.
Its antibacterial activity against S. marcescens and P. aeruginosa was more prominent than those of gentamicin and other cephems. This is a unique advantage of ceftazidime, because the activity of other cephems against S. marcescens and P. aeruginosa has not been superior to that of gentamicin.
2) Clinical studies
Seventeen patients with complicated urinary tract infections were treated with ceftazidime at a daily dose of 1.0-4.0g by drip infusion for 5 or 10 days. One patient with postoperative wound infection received ceftazidime at a daily dose of 3.0g for 13 days. In the former 17 cases, excellent clinical response was achieved in 3, moderate in 13. The overall clinical efficacy rate was 94.1%. The latter case showed good clinical response. As for side effects, no patient showed either subjective or objective symptoms attributable to the administration of ceftazidime.
In hematogram or blood chemistry after the administration of ceftazidime, no abnormal values were observed.